JP2010528013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010528013A5 JP2010528013A5 JP2010509385A JP2010509385A JP2010528013A5 JP 2010528013 A5 JP2010528013 A5 JP 2010528013A5 JP 2010509385 A JP2010509385 A JP 2010509385A JP 2010509385 A JP2010509385 A JP 2010509385A JP 2010528013 A5 JP2010528013 A5 JP 2010528013A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- administered
- composition according
- interferon
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93110807P | 2007-05-21 | 2007-05-21 | |
| US99443007P | 2007-09-19 | 2007-09-19 | |
| PCT/US2008/006572 WO2008144072A1 (en) | 2007-05-21 | 2008-05-21 | Dose forms comprising vx- 950 and their dosage regimen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014034070A Division JP2014132015A (ja) | 2007-05-21 | 2014-02-25 | Ｖｘ−９５０を含む用量形態およびそれらの投与レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010528013A JP2010528013A (ja) | 2010-08-19 |
| JP2010528013A5 true JP2010528013A5 (enExample) | 2011-07-07 |
Family
ID=39597267
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010509385A Pending JP2010528013A (ja) | 2007-05-21 | 2008-05-21 | Ｖｘ−９５０を含む用量形態およびそれらの投与レジメン |
| JP2014034070A Pending JP2014132015A (ja) | 2007-05-21 | 2014-02-25 | Ｖｘ−９５０を含む用量形態およびそれらの投与レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014034070A Pending JP2014132015A (ja) | 2007-05-21 | 2014-02-25 | Ｖｘ−９５０を含む用量形態およびそれらの投与レジメン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100189688A1 (enExample) |
| EP (1) | EP2157974A1 (enExample) |
| JP (2) | JP2010528013A (enExample) |
| CN (1) | CN101854936A (enExample) |
| AU (1) | AU2008254435A1 (enExample) |
| CA (1) | CA2688554A1 (enExample) |
| MX (1) | MX2009012598A (enExample) |
| WO (1) | WO2008144072A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| EP2328656A1 (en) * | 2008-09-24 | 2011-06-08 | Vertex Pharmaceuticals Incorporated | Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis " |
| WO2010053942A1 (en) * | 2008-11-05 | 2010-05-14 | Vertex Pharmaceuticals Incorporated | Methods for treating hepatitis c virus infection |
| EP2396028A2 (en) | 2009-02-12 | 2011-12-21 | Vertex Pharmceuticals Incorporated | Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| CN102844030A (zh) | 2010-01-29 | 2012-12-26 | 沃泰克斯药物股份有限公司 | 用于治疗丙型肝炎病毒感染的疗法 |
| WO2011156545A1 (en) | 2010-06-09 | 2011-12-15 | Vertex Pharmaceuticals Incorporated | Viral dynamic model for hcv combination therapy |
| EP2593105A1 (en) | 2010-07-14 | 2013-05-22 | Vertex Pharmaceuticals Incorporated | Palatable pharmaceutical composition comprising vx-950 |
| CA2811203C (en) | 2011-10-21 | 2015-05-05 | Abbvie Inc. | Methods for treating hcv |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US20130195797A1 (en) | 2012-01-31 | 2013-08-01 | Vertex Pharmaceuticals Incorporated | High potency formulations of vx-950 |
| JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY141025A (en) * | 2004-10-29 | 2010-02-25 | Vertex Pharma | Dose forms |
-
2008
- 2008-05-21 AU AU2008254435A patent/AU2008254435A1/en not_active Abandoned
- 2008-05-21 CA CA2688554A patent/CA2688554A1/en not_active Abandoned
- 2008-05-21 CN CN200880025665A patent/CN101854936A/zh active Pending
- 2008-05-21 MX MX2009012598A patent/MX2009012598A/es not_active Application Discontinuation
- 2008-05-21 WO PCT/US2008/006572 patent/WO2008144072A1/en not_active Ceased
- 2008-05-21 JP JP2010509385A patent/JP2010528013A/ja active Pending
- 2008-05-21 EP EP08754666A patent/EP2157974A1/en not_active Withdrawn
-
2009
- 2009-11-20 US US12/592,225 patent/US20100189688A1/en not_active Abandoned
-
2014
- 2014-02-25 JP JP2014034070A patent/JP2014132015A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008518943A5 (enExample) | ||
| Li et al. | Current therapy for chronic hepatitis C: The role of direct-acting antivirals | |
| HRP20110169T1 (hr) | Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c | |
| JP2011519364A5 (enExample) | ||
| JP2007522237A5 (enExample) | ||
| JP2013529627A5 (enExample) | ||
| BRPI0811020A2 (pt) | Composto, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática, de intensificação da função hepática em indivíduo com infecção do vírus da hepatite c e métodos de síntese de compostos, de administração de inibidor da infecção do vírus da hepatite c (hcv) e de distribuição de forma de dosagem oral. | |
| JP2007509950A5 (enExample) | ||
| JP2012517478A5 (enExample) | ||
| RU2012136824A (ru) | Способы лечения вирусной инфекции гепатита с | |
| CA2573207A1 (en) | Use of a combination of cyclosporin and pegylated interferons for treating hepatitis c (hcv) | |
| JP2014530874A5 (enExample) | ||
| BRPI0811447A2 (pt) | Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c. | |
| EP2341065A3 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4a protease | |
| RU2007119725A (ru) | Лекарственные формы | |
| US20080075695A1 (en) | Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein | |
| RU2013119607A (ru) | Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
| WO2006016930A3 (en) | Methods for treating hcv infection | |
| EP2467144A1 (en) | Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis | |
| CL2011000571A1 (es) | Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma. | |
| JP2013518124A5 (enExample) | ||
| PH12012500827A1 (en) | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin | |
| RU2010153688A (ru) | Режим дозирования телапревира | |
| US20140135259A1 (en) | Treatment of hepatitis c virus | |
| JP2012503669A5 (enExample) |